Market Sentiment Around Loss-Making Spago Nanomedical AB (publ) (STO:SPAGO)

We feel now is a pretty good time to analyse Spago Nanomedical AB (publ)'s (STO:SPAGO) business as it appears the company may be on the cusp of a considerable accomplishment. Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. The kr70m market-cap company announced a latest loss of kr33m on 30 December 2024 for its most recent financial year result. Many investors are wondering about the rate at which Spago Nanomedical will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

View our latest analysis for Spago Nanomedical

Consensus from 2 of the Swedish Biotechs analysts is that Spago Nanomedical is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of kr42m in 2026. The company is therefore projected to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 19% year-on-year, on average, which seems relatively fair. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Spago Nanomedical's upcoming projects, but, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means a double-digit growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one aspect worth mentioning. Spago Nanomedical currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Spago Nanomedical, so if you are interested in understanding the company at a deeper level, take a look at Spago Nanomedical's company page on Simply Wall St. We've also compiled a list of important aspects you should further research:

1. Historical Track Record: What has Spago Nanomedical's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Spago Nanomedical's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.